Throughout his 25-year career at Pfizer, Philip Inskeep, Ph.D., has studied the process of bodily absorption, distribution, metabolism, and excretion of potential drugs for the treatment of diabetes, atherosclerosis and infectious diseases. An associate research fellow in Pfizer’s Pharmacokinetics, Dynamics and Metabolism department, Dr. Inskeep’s extensive knowledge in this research area also includes veterinary drug disposition in both livestock and companion animals.

Dr. Inskeep earned a bachelor’s degree in biochemistry at Virginia Polytechnic Institute and State University and continued his education at the Pennsylvania State University, where he obtained his doctorate in biochemistry. He also completed a two-year fellowship at Vanderbilt University, prior to joining Pfizer’s Drug Metabolism department in 1984. Dr. Inskeep then spent seven years in the company’s Veterinary Medicine Safety and Metabolism group, beginning in 1995, and has assumed various leadership roles within his current department since 2002.

He is the author of more than 30 scientific articles and two book chapters. Currently, Dr. Inskeep is a member of the American Society for Pharmacology and Experimental Therapeutics, the International Society for the Study of Xenobiotics, and the editorial boards of Xenobiotica and Drug Metabolism and Disposition.